Affinity Asset Advisors, LLC Bluebird Bio, Inc. Call Options Transaction History

Affinity Asset Advisors, LLC

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2021 Aug 13, 2021	SELL	$18.04 - $22.09 $902,000 - $1.1 Million	-50,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$16.59 - $33.89 $829,500 - $1.69 Million	50,000 New	50,000 $1.51 Million

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $601M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.